Product Commercialization, Going Beyond Demand Generation

The pharmaceutical market has rapidly evolved and is now comprised of high-cost, complex specialty drugs, intended for specific rare and orphan disease as well as cell and gene therapies. Many of these new specialty drugs offer hope for previously untreatable conditions and greatly improve patient quality of life and in the case of cell and gene therapies, potential cures. However, the pharmaceutical landscape, and the requirements and knowledge needed to successfully commercialize these new specialty drugs, have grown increasingly complex and focus on narrow patient populations and indications.

In this informative whitepaper from Blue Fin Group, experts demystify patient funnel questions and consider the complexities of today’s market.

Download now!

Rg Paper
adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article